Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Teva
US Army
Cerilliant
Daiichi Sankyo
Accenture
Covington
Colorcon
Express Scripts

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TEMSIROLIMUS

« Back to Dashboard

Clinical Trials for Temsirolimus

Trial ID Title Status Sponsor Phase Summary
NCT00003712 CCI-779 in Treating Patients With Advanced Solid Tumors Completed National Cancer Institute (NCI) Phase 1 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of CCI-779 in treating patients who have advanced solid tumors.
NCT00003712 CCI-779 in Treating Patients With Advanced Solid Tumors Completed University of Texas Phase 1 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of CCI-779 in treating patients who have advanced solid tumors.
NCT00003712 CCI-779 in Treating Patients With Advanced Solid Tumors Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 1 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of CCI-779 in treating patients who have advanced solid tumors.
NCT00003712 CCI-779 in Treating Patients With Advanced Solid Tumors Completed The University of Texas Health Science Center at San Antonio Phase 1 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of CCI-779 in treating patients who have advanced solid tumors.
NCT00012142 CCI-779 in Treating Patients With Prostate Cancer Completed National Cancer Institute (NCI) Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to determine the effectiveness of CCI-779 in treating patients who have progressive prostate cancer.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Temsirolimus

Condition Name

Condition Name for Temsirolimus
Intervention Trials
Renal Cell Carcinoma 13
Advanced Cancer 10
Unspecified Adult Solid Tumor, Protocol Specific 10
Kidney Cancer 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Temsirolimus
Intervention Trials
Carcinoma 47
Carcinoma, Renal Cell 41
Lymphoma 25
Neoplasms 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Temsirolimus

Trials by Country

Trials by Country for Temsirolimus
Location Trials
United States 924
Canada 88
Germany 37
France 29
Australia 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Temsirolimus
Location Trials
Texas 57
California 45
New York 42
Pennsylvania 39
Illinois 38
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Temsirolimus

Clinical Trial Phase

Clinical Trial Phase for Temsirolimus
Clinical Trial Phase Trials
Phase 4 3
Phase 3 8
Phase 2 89
[disabled in preview] 104
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Temsirolimus
Clinical Trial Phase Trials
Completed 102
Active, not recruiting 42
Terminated 25
[disabled in preview] 33
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Temsirolimus

Sponsor Name

Sponsor Name for Temsirolimus
Sponsor Trials
National Cancer Institute (NCI) 81
Pfizer 31
Wyeth is now a wholly owned subsidiary of Pfizer 24
[disabled in preview] 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Temsirolimus
Sponsor Trials
Other 167
Industry 99
NIH 82
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
US Department of Justice
Teva
Fish and Richardson
Argus Health
Merck
Baxter
Cantor Fitzgerald
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.